2 days Ago By Defense World Staff
Quest Partners LLC boosted its position in shares of Sage Therapeutics, Inc. ( NASDAQ:SAGE – Free Report ) by 14.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission.
The fund owned 11,763 shares of the biopharmaceutical company’s stock after buying an additional 1,486 shares during the quarter. Quest Partners LLC’s holdings in Sage Therapeutics were worth $128,000 as of its most recent filing with the Securities & Exchange Commission. Several other institutional investors have also added to or reduced their stakes in the company.
Lazard Asset Management LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth about $127,000. Virtu Financial LLC purchased a new stake in Sage Therapeutics in the 1st quarter worth approximately $187,000. China Universal Asset Management Co.
Ltd. lifted its holdings in Sage Therapeutics by 66.6% in the 1st quarter.
China Universal Asset Management Co. Ltd. now owns 11,554 shares of the biopharmaceutical company’s stock worth $217,000 after buying an additional 4,617 shares during the period.
ProShare Advisors LLC grew its position in shares of Sage Therapeutics by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 1,130 shares during the last quarter.
Finally, SG Americas Securities LLC bought a new position in shares of Sage Therapeutics during the second quarter valued at approximately $177,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.
Sage Therapeutics Stock Performance Shares of Sage Therapeutics stock opened at $7.57 on Tuesday. The company has a 50-day simple moving average of $9.
33 and a two-hundred day simple moving average of $12.56. The stock has a market capitalization of $462.
15 million, a PE ratio of -0.90 and a beta of 0.91.
Sage Therapeutics, Inc. has a 52-week low of $7.19 and a 52-week high of $28.
26. Wall Street Analysts Forecast Growth SAGE has been the topic of several recent analyst reports. JPMorgan Chase & Co.
cut their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th.
TD Cowen cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $16.00 to $10.00 in a research report on Tuesday, July 30th.
HC Wainwright reissued a “neutral” rating and issued a $25.00 price target on shares of Sage Therapeutics in a research note on Friday, August 2nd. Citigroup initiated coverage on Sage Therapeutics in a research report on Wednesday, May 29th.
They set a “sell” rating and a $8.00 price objective on the stock. Finally, Scotiabank decreased their target price on Sage Therapeutics from $19.
00 to $17.00 and set a “sector outperform” rating for the company in a research report on Thursday, July 25th. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating and one has assigned a buy rating to the stock.
According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $16.06.
Get Our Latest Analysis on Sage Therapeutics Sage Therapeutics Company Profile ( Free Report ) Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Featured Stories Five stocks we like better than Sage Therapeutics How to buy stock: A step-by-step guide for beginners Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible High Flyers: 3 Natural Gas Stocks for March 2022 Roblox’s Growth Beyond Kids: Stock Set for Major Moves How to Calculate Return on Investment (ROI) 5 Oversold Stocks to Buy Right Now Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
